TOCA 511 & TOCA FC: PRE-CLINICAL PROOF OF CONCEPT IN MEDULLOBLASTOMA

被引：0

作者：

Richardson, Angela M. ^{[1
,2
]}

Collins, Sara A. ^{[3
]}

Inagaki, Akihito ^{[3
]}

Armstrong, L. ^{[4
]}

Roussel, Martine ^{[5
]}

Jolly, Douglas ^{[6
]}

Robbins, David J. ^{[7
,8
]}

Ayad, Nagi ^{[9
]}

Kasahara, Noriyuki ^{[10
,11
]}

机构：

[1] Univ Miami, Dept Neurol Surg, Miami, FL USA

[2] Jackson Hlth Syst, Neurosurg Program, Miami, FL USA

[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[4] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[5] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA

[6] Tocagen Inc, San Diego, CA USA

[7] Univ Miami, Dept Surg, Miami, FL USA

[8] Univ Miami, Dept Biochem, Miami, FL USA

[9] Univ Miami, Miami, FL USA

[10] Univ Miami, Dept Cell Biol, Miami, FL USA

[11] Univ Miami, Dept Pathol, Miami, FL USA

来源：

NEURO-ONCOLOGY | 2017年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PDTM-19

引用

页码：193 / 193

页数：1

共 50 条

[21] IMMUNOLOGICAL ACTIVATION IN RESPONDING PATIENTS WITH RECURRENT HGG AFTER TREATMENT WITH TOCA 511 & TOCA FC: RESULTS FROM A PHASE 1 TRIAL
Ostertag, Derek
Accomando, William
Hogan, Daniel
Diago, Oscar
Gammon, Dawn
Haghighi, Ali
Mitchell, Leah
Rodriguez-Aquirre, Maria
Cloughesy, Timothy
Kalkanis, Steven
Mikkelsen, Tom
Landolfi, Joseph
Chen, Clark
Vogelbaum, Michael
Gruber, Harry
Das, Asha
Jolly, Douglas
NEURO-ONCOLOGY, 2017, 19 : 31 - 32
[22] DURABLE RESPONSES OBSERVED IN IDH1 WILDTYPE AND MUTANT RECURRENT HIGH GRADE GLIOMA (rHGG) WITH TOCA 511 & TOCA FC TREATMENT
Cloughesy, Timothy
Landolfi, Joseph
Vogelbaum, Michael
Ostertag, Derek
Elder, Bradley
Carter, Bob
Chen, Clark
Kalkanis, Steven
Lai, Albert
Mikkelsen, Tom
Nghiemphu, Phioanh
Piccioni, David
Accomando, William
Diago, Oscar
Hogan, Daniel
Jolly, Douglas
Wood, Katie
Yang, Liqiang
Gruber, Harry
Das, Asha
Walbert, Tobias
NEURO-ONCOLOGY, 2017, 19 : 26 - 26
[23] INVESTIGATION OF ANTI-TUMOR CELLULAR IMMUNE RESPONSE ELICITED BY TOCA 511 & TOCA FC THERAPY IN A RECURRENT HGG PHASE 1 TRIAL
Ostertag, Derek
Cloughesy, Timothy
Kalkanis, Steven
Mikkelsen, Tom
Landolfi, Joseph
Carter, Bob
Chen, Clark
Das, Asha
Jolly, Douglas
Gruber, Harry
Vogelbaum, Michael
NEURO-ONCOLOGY, 2016, 18 : 21 - 21
[24] Toca 511 & Toca FC: Evaluation of Durable Response Rate in the Post-Resection Setting and Association with Survival in Patients with Recurrent High Grade Glioma
Cloughesy, Timothy
Landolfi, Joseph
Vogelbaum, Michael
Ostertag, Derek
Elder, Bradley
Carter, Bob
Chen, Clark
Kalkanis, Steven
Kesari, Santosh
Lai, Albert
Lee, Ian
Liau, Linda
Nghiemphu, Phioanh
Piccioni, David
Accomando, William
Diago, Oscar
Hogan, Daniel
Jolly, Douglas
Wood, Katie
Kheoh, Thian
Gruber, Harry
Das, Asha
Walbert, Tobias
NEUROLOGY, 2018, 90
[25] Mechanism of Action of Toca 511 and 5-FC in Animal Models and Cancer Patients
Jolly, Douglas J.
Accomando, William P.
Cloughesy, Timothy F.
Kalkanis, Steven N.
Mikkelsen, Tom
Landolfi, Joseph
Carter, Bob
Chen, Clark C.
Vogelbaum, Michael A.
Elder, James
Piccioni, David
Walbert, Tobias
Hogan, Daniel
Diago, Oscar
Kheoh, Thian
Haghighi, Ali
Gammon, Dawn
Montellano, Tiffany
Kasahara, Noriyuki
Rodriguez-Aguirre, Maria
Mendoza, Daniel
Gruber, Harry E.
Ibanez, Carlos
Ostertag, Derek
MOLECULAR THERAPY, 2019, 27 (04) : 4 - 4
[26] Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC.
Cloughesy, Timothy Francis
Ostertag, Derek
Landolfi, Joseph C.
Walbert, Tobias
Vogelbaum, Michael A.
Elder, J. Bradley
Bloomfield, Steven
Carter, Bob
Chen, Clark
Kalkanis, Steven N.
Kesari, Santosh
Lai, Albert
Lee, Ian
Liau, Linda M.
Mikkelsen, Tom
Nghiemphu, Phioanh Leia
Piccioni, David Eric
Jolly, Douglas J.
Gruber, Harry E.
Das, Asha
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[27] EVIDENCE SUPPORTINGMECHANISMOFACTIONAND DRUG ACTIVITY IN PHASE I TRIAL OF PATIENTS WITH RECURRENT HIGH GRADE GLIOMA ADMINISTERED TOCA 511 AT SURGICAL RESECTION FOLLOWED BY TOCA FC
Cloughesy, Timothy F.
Liau, Linda M.
Chiocca, E. Antonio
Jolly, Douglas J.
Robbins, Joan M.
Ostertag, Derek
Ibanez, Carlos E.
Gruber, Harry E.
Kasahara, Noriyuki
Vogelbaum, Michael A.
Kesari, Santosh
Mikkelsen, Tom
Kalkanis, Steven
Landolfi, Joseph
Bloomfield, Stephen
Foltz, Greg
Pertschuk, Dan
NEURO-ONCOLOGY, 2013, 15 : 69 - 69
[28] Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer
Collins, Sara A.
Shah, Ashish H.
Ostertag, Derek
Kasahara, Noriyuki
Jolly, Douglas J.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (09) : 1199 - 1214
[29] COMPLEMENTARY CLINICAL AND ANCILLARY DATA FROM 123 PATIENTS WITH RECURRENT HIGH GRADE GLIOMA FROM THREE PHASE 1 TRIALS OF TOCA 511 AND TOCA FC: UPDATE AND JUSTIFICATION FOR A PHASE 2/3 TRIAL
Aghi, Manish
Vogelbaum, Michael
Kalkanis, Steven
Bota, Daniela
Carter, Bob
Chen, Clark
Elder, Bradley
Engh, Johnathan
Goldlust, Samuel
Kaptain, George
Kesari, Santosh
Landolfi, Joseph
Liau, Linda
Mikkelsen, Tom
Piccioni, David
Portnow, Jana
Singer, Samuel
Walbert, Tobias
Gruber, Harry
Ibanez, Carlos
Jolly, Douglas
Mitchell, Leah
Ostertag, Derek
Shorr, Jolene
Yang, Liqiang
Das, Asha
Cloughesy, Timothy
NEURO-ONCOLOGY, 2016, 18 : 18 - 18
[30] Treatment of Recurrent HGG Patients with the Retroviral Replicating Vector Toca 511 and Toca FC Gives Durable Responses and Survival Lasting 3 Years or Longer: Immune Mechanisms and Molecular Analyses of Tumors
Das, Asha
Ostertag, Derek
Hogan, Daniel
Accomando, William
Diago, Oscar
Haghighi, Ali
Gammon, Dawn
Rodriguez-Aguirre, Maria
Mitchell, Leah
Kalkanis, Steven
Mikkelsen, Tom
Landolfi, Joseph
Carter, Bob
Chen, Clark
Vogelbaum, Michael
Cloughesy, Timothy
Gruber, Harry
Jolly, Douglas
MOLECULAR THERAPY, 2018, 26 (05) : 160 - 160

← 1 2 3 4 5 →